Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TNGX
TNGX | US
26.39
USD-0.25
-0.94%
TNGX | US
About TNGX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
20/04/2026
Close
26.39
Open
26.86
High
27.16
Low
26.04
Tango Therapeutics Inc. a biotechnology company discovers and develops drugs for the treatment of cancer. Its lead program is TNG908 a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462 an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260 a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348 an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics Inc. has a strategic collaboration with Gilead Sciences Inc. for the discovery development and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston Massachusetts.
View LessTNGX | US
Risk
78.7
Sharpe
17.82
Luna's Score
61/100
Recommendation
Hold
Luna says (TNGX | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
86.6%1 month
78.7%3 months
94.2%6 months
92.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.23
Debt to equity
0.15
Debt to assets
0.10
Ent. to EBITDA
-0.91
Ent. to rev.
12.12
PEG
-
Other Fundamentals
EBITDA
-129.96M
MarketCap
2.83B
MarketCap(USD)
2.83B
Div. yield
-
Op. margin
-148.69
Erngs. growth
-
Rev. growth
36.10
Ret. on equity
-50.58
Short ratio
8.27
Short perc.
18.63
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
7.92
Range1M
8.65
Range3M
16.36
Volumes: Market Activity
Rel. volume
0.54
Price X volume
38.96M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.91 | - | Cheaper |
| Ent. to Revenue | 12.12 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.23 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 94.16 | - | Riskier |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 2.83B | - | Emerging |
